Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

Phase 2

Completed

• Conditions: Graft Versus Host Disease
• Interventions: Drug: Imatinib Mesylate and Nilotinib

• Registration Number: NCT02891395
• Lead Sponsor: University Hospital, Lille

Brief Summary

Open label non-randomized multicenter phase 2 trial with direct individual benefice

Detailed Description

Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year. Patients, who discontinue imatinib mesylate at 3 months for lack of response (no response = stable disease), those who experience progression at any time, those who relapse after an initial response at any time or those who discontinue for toxicity at any time, will go to the salvage phase.

Salvage phase:

Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year.

Study Timeline

• Study Start: 2012-12-24
• Study First Submitted: 2016-09-01
• Study First Submitted QC: 2016-09-01
• Study First Posted: 2016-09-07
• Primary Completion: 2017-07-26
• Study Completion: 2017-07-26
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-09
• Last Update Posted: 2019-07-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

Induction phase (IM):

• Patients aged ≥18 years to 75 years

• Patients who underwent allo-SCT for a hematological disorder

• Body weight ≥ 40 Kg.

• Confirmed diagnosis of cGVHD resistant to at least one systemic immunosuppressive therapy. The diagnosis of cGHVD should be based on the NIH Working Group Consensus (www.asbmt.org/gvhd/index.htm). Grading of cGVHD will be based on clinical manifestations including:

  1. ocular, oral and mucosal symptoms;
  2. performance status;
  3. evaluation of pulmonary functions;
  4. cutaneous evaluation;
  5. evaluation of musculo-skeletal manifestations;
  6. evaluation of liver involvement;

• Any source of hematopoietic stem cell is allowed

• Both myeloablative and nonmyeloablative conditioning regimens are authorized.

• Absence of contra-indications to the use of IM or Nilotinib

• Patient having French health care coverage

• Female patients of childbearing potential must have before initiation of study drug and agree to have efficient contraceptive precautions throughout the trial and for 3 months after the end of the trial.

• Signed informed consent.

Salvage phase (Nilotinib) :

Patients enrolled in the first phase and who failed to IM:

• Patients, who discontinue imatinib mesylate at 3 months for lack of response (no response = stable disease),
• those who experience progression at any time,
• those who relapse after an initial response at any time
• or those who discontinue for toxicity at any time.

Exclusion Criteria

• Patient developing acute GVHD (whether early or "late onset" form)

• First episode of cGVHD

• Patient who received IM or Nilotinib treatment or any other TKI after transplant 3 months before the inclusion on the study

• Patient treated by TKI for a GVHD

• Contra-indication to IM or Nilotinib

• Neutropenia < 0.5 G/L

• Uncontrolled systemic infection which can be associated, according to the investigator, to an enhanced risk of patient's death during the first month of treatment

• Severe neurological or psychiatric disorders

• Pregnancy or lactation

• Known uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction < 40% (cardiac tests as clinically indicated)

• Recurrence of cancer for which the transplant was done except for presence of minimal residual disease by PCR

• Patients with secondary malignancy ≤ 2 years prior study-entry except:

  • Basal cell carcinoma of the skin
  • Squamous cell carcinoma of the skin
  • Carcinoma in situ of the cervix
  • Carcinoma in situ of the breast
  • Prostate cancer (Tumor, Node, Metastasis [TNM] stage T1a or T1b)

• Patients in emergency situation

• Patients kept in detention

• Patients unable or unwilling to comply with the protocol requirements

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
open-label	Imatinib Mesylate and Nilotinib	Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year. Salvage phase: Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year.

Primary Outcome Measures

Name	Time	Method
Response rate at 3 months (complete and partial remission) after salvage treatment with Nilotinib in patients with chronic GVHD who failed Imatinib Mesylate (IM)	Between Baseline and minimum 12 weeks of treatment	Response rate at 3 months (complete and partial remission) after salvage treatment with Nilotinib in patients with chronic GVHD who failed Imatinib Mesylate (IM)

Secondary Outcome Measures

Name	Time	Method
Best response to IM within 12 months and the duration of this response	From 12 to 52 weeks of Imatinib Mesylate treatment
use of systemic secondary treatment due to intolerance to Nilotinib	From baseline to 12 weeks of Nilotinib treatment	measure intolerance by Nilotinib failure
Best response rate to Nilotinib within 12 months and the duration of this response	From 12 to 52 weeks of Nilotinib treatment
use of systemic secondary treatment due to intolerance to IM	From baseline to 12 weeks of IM treatment	measure intolerance by IM failure

Trial Locations

Locations (22)

CHU Clémenceau; 🇫🇷 Caen, France

CHU Besançon; 🇫🇷 Besancon, France

Hopital Morvan; 🇫🇷 Brest, France

Institut Paoli Calmettes; 🇫🇷 Marseille, France

Hopital NECKER; 🇫🇷 Paris, France

CHU d'Amiens; 🇫🇷 Amiens, France

CHU d'Angers; 🇫🇷 Angers, France

CHU Purpan; 🇫🇷 Toulouse, France

CHU Bordeaux; 🇫🇷 Bordeaux, France

Centre Henri Becquerel; 🇫🇷 Rouen, France

HIA de Percy; 🇫🇷 Clamart, France

CHU de Clermont Ferrand; 🇫🇷 Clermont Ferrand, France

CHU Grenoble; 🇫🇷 Grenoble, France

Diseases of Blood Service HURIEZ hospital CHRU de LILLE; 🇫🇷 LIlle, France

Centre hospitalier et régional de Lille; 🇫🇷 Lille, France

CHU de Lyon; 🇫🇷 Lyon, France

Hôpital Saint Eloi; 🇫🇷 Montpellier, France

CHU Hotel Dieu; 🇫🇷 Nantes, France

CHU de Nice; 🇫🇷 Nice, France

Hôpital pitié Salpetrière; 🇫🇷 Paris, France

CHU de STRASBOURG; 🇫🇷 Strasbourg, France

CHU Sart Tilman; 🇧🇪 Liège, Belgium